Corpus Intelligence IC Memo — DALLAS MEDICAL CENTER 2026-04-26 14:10 UTC
IC Memo — DALLAS MEDICAL CENTER
Investment Committee Memorandum | TX | 119 beds | Grade D | EBITDA uplift $2.5M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

DALLAS MEDICAL CENTER

CCN 450379 | DALLAS, TX | 119 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

DALLAS MEDICAL CENTER is a 119-bed under-performing / distressed in DALLAS, TX with $34.1M in net patient revenue and a -55.5% operating margin. The hospital serves a payer mix of 27.3% Medicare, 1.1% Medicaid, and 71.6% commercial.

Thesis: Undervalued. Our ML models identify $2.5M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -55.5% to -48.1% (+736bps).

Net Revenue HCRIS$34.1M
Current EBITDA COMPUTED$-18.9M
Operating Margin COMPUTED-55.5%
Occupancy HCRIS14.4%
Revenue / Bed COMPUTED$287K
Net-to-Gross HCRIS14.3%
Distress Probability ML55.3%

2. Market Context & Competitive Position

583
TX Hospitals
-0.7%
State Median Margin
181
Comparable Hospitals

TX has 583 Medicare-certified hospitals with a median operating margin of -0.7%. The target's margin of -55.5% places it below the state median. Among 181 size-comparable peers (60-238 beds), the median margin is 2.2%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (60-238), prioritizing same-state peers. 181 hospitals in the comp set.

HospitalStateBedsRevenueMargin
DALLAS MEDICAL CENTER (Target)TX119$34.1M-55.5%
DRISCOLL CHILDRENS HOSPITALTX215$694.3M29.4%
ROUND ROCK HOSPITALTX165$681.4M8.7%
HILLCREST BAPTIST MEDICAL CENTTX236$464.8M-6.7%
THE HEART HOSPITAL BAYLOR PLANTX109$464.6M25.7%
DELL SETON MEDICAL CENTER AT TTX225$438.6M-4.2%
COVENANT CHILDRENS HOSPITALTX181$410.3M15.5%
COLLEGE STATION HOSPITALTX135$397.7M-0.9%
MEMORIAL HERMANN KATYTX196$381.4M13.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.5M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$716K+210bp18mo
Cost to Collect4.5%2.5%$682K+200bp12mo
Denial Rate Reduction12.0%6.5%$675K+198bp12mo
A/R Days Reduction5200.0%3800.0%$415K+122bp9mo
Clean Claim Rate88.0%96.0%$22K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$716K
Cost to Collect
$682K
Denial Rate Reduction
$675K
A/R Days Reduction
$415K
Clean Claim Rate
$22K
Total EBITDA Uplift$2.5M
Current EBITDA$-18.9M
+ RCM Uplift+$2.5M
Pro Forma EBITDA$-16.4M
Current Margin-55.5%
Pro Forma Margin-48.1%
WC Released (1x)$1.3M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-29.1M$-99.7M0.00x-100.0%
Base (11x exit)10.0x11.0x$-29.1M$-119.1M0.00x-100.0%
Bull Case9.0x11.0x$-26.2M$-120.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-26.2M$-139.0M0.00x-100.0%
Bear Case11.0x10.0x$-32.0M$-102.8M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-32.0M$-123.5M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 14.4%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 55.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 181 hospitals with 60-238 beds
  • Same-state prioritization (n=182)
  • Comp margins: P25=-8.4% / P50=2.2% / P75=11.7%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.